Yasunori Mitsuoka

This inventor holds 6 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Shionogi Company Limited, E-Na Biotec Inc., Other. Active years: 2014-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yasunori Mitsuoka. Retrieved from https://idiyas.com/inventor/yasunori-mitsuoka

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 5)

% Patents Active = 50.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 10)

Average Co-Inventor Count = 4.1

ph-index = 2

Forward Citations = 15(Granted Patents)

Location History:

Osaka, JP (2021)
Toyonaka, JP (2014 - 2023)

Company Filing History:

5 out of 1,001

Shionogi Company Limited

1 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2014-2023

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11638717 - Complex of nucleic acid medicine and multibranched lipid (2023-05-02),

2. 11041152 - MicroRNA-143 derivative (2021-06-22),

3. 10940201 - Nucleic acid derivative having immunostimulatory activity (2021-03-09),

4. 9315535 - Nucleoside and nucleotide having nitrogen-containing heterocycle structure (2016-04-19),

5. 8927721 - Naphthyridine derivative (2015-01-06),

6. 8883779 - Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them (2014-11-11),

Title: **Yasunori Mitsuoka: A Pioneer in Nucleic Acid Medicine**

Introduction

Yasunori Mitsuoka, a notable inventor based in Toyonaka, Japan, has made significant contributions in the field of nucleic acid medicine. With a solid portfolio of six patents, his innovations are paving the way for advancements in therapeutic treatments. His latest inventions demonstrate a commitment to enhancing the efficacy of nucleic acid-based therapies.

Latest Patents

Mitsuoka's most recent patents include groundbreaking creations aimed at improving the effect of nucleic acid medicines. One such invention is a complex that incorporates multibranched lipids linked to oligonucleotide strands, particularly those associated with gene expression suppression. This novel complex serves to enhance the effectiveness of nucleic acid treatments. Additionally, he has developed derivatives of MicroRNA-143, which hold promise as oligonucleotide therapeutics, further highlighting his innovative approach to gene therapy.

Career Highlights

Throughout his career, Yasunori Mitsuoka has collaborated with prominent corporations such as Shionogi & Company Limited and E-na Biotec Inc. His work within these organizations has been crucial in translating theoretical concepts into practical applications in the medical field. Mitsuoka's six patents underscore his dedication to advancing medical technology and improving patient outcomes.

Collaborations

Mitsuoka's innovative journey has been supported by collaborations with talented colleagues, including Akira Kugimiya and Mitsuaki Sekiguchi. Together, they have contributed to the research and development of advanced therapeutic solutions, further enhancing the impact of their combined expertise in nucleic acid medicine.

Conclusion

Yasunori Mitsuoka stands out as a pivotal figure in the realm of medical innovation, particularly in nucleic acid therapies. His ongoing efforts to create effective therapeutic complexes and derivatives demonstrate a strong commitment to improving healthcare solutions. With a promising portfolio of patents and collaborations, Mitsuoka continues to inspire future innovations in the medical field.

Profile summary based on public USPTO records.